The most advanced radiolabelled anti-CD22 Ab is 90Y-epratuzumab, showing anti-tumor effects in both indolent and aggressive NHL in a phase I trial with mainly grade 3–4 hematological toxicities (119). This evidence concerns the gene CD22 and non-Hodgkin lymphoma.